Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTR
NCT03506061Phase 2Completed
- Sponsor
- Emory University
- Start
- Sep 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Emory University. Primary endpoints: Percent Predicted Forced Expiratory Volume in One Second at Day 28, Sweat Chloride at Day 28 and 1 more. Started Sep 2019; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03506061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506061.